Introduction
============

Liver cancer is one of the most common types of cancers in the world, with \~841,000 newly diagnosed cases and 782,000 deaths globally per year, according to the global burden data in 2018. Hepatocellular carcinoma (HCC) constitutes 75--85% of liver cancer cases globally ([@b1-ol-0-0-11581]). In spite of the rapid development of clinical treatment methods in recent years, the prognosis of HCC patients remains dismal ([@b2-ol-0-0-11581]). Overall, the choice of surgical approach significantly affects prognosis and therefore, should be carefully considered ([@b3-ol-0-0-11581]).

In current clinical practice, the Barcelona Clinic Liver Cancer staging system ([@b4-ol-0-0-11581]) is recommended as the standard for surgical approach selection by both the European Association for the Study of the Liver and the American Association for the Study of Liver Disease ([@b5-ol-0-0-11581],[@b6-ol-0-0-11581]). According to this standard, curative treatments are recommended as the optimal choice only for patients with very-early-stage and early-stage tumors (Barcelona Clinic Liver Cancer staging 0-A; solitary tumors or multinodular tumors with ≤3 nodules and size ≤3 cm with no vascular invasion or extrahepatic spread, Child-Turcotte-Pugh A or B, performance status 0) ([@b7-ol-0-0-11581]). Kutlu *et al* ([@b8-ol-0-0-11581]) demonstrated that radiofrequency ablation (RFA) is an appropriate method of treatment for patients with tumors measuring ≤30 mm, but that overall and cancer-specific survival (CSS) are worse for RFA compared with surgical resection or transplantation for tumors \>30 mm. For patients with unresecTable tumors, Shimose *et al* ([@b9-ol-0-0-11581]) suggested that transcatheter arterial chemoembolization (TACE) combined with RFA may prolong survival compared with TACE alone. However, some guidelines recommend surgical treatment for a broader spectrum of patients with HCC, such as the Asian Pacific Association for the Study of the Liver ([@b10-ol-0-0-11581]), the American Hepato-Pancreato-Biliary Association ([@b11-ol-0-0-11581]), the Korean Liver Cancer Study Group ([@b12-ol-0-0-11581]) and the Japan Society of Hepatology ([@b13-ol-0-0-11581]). In addition, Hyun *et al* ([@b7-ol-0-0-11581]) in 2019 performed a systematic review and reported that surgical treatment provides survival benefits in advanced-stage patients with HCC compared with chemoembolization. Due to these inconsistencies, further exploration is needed to establish the best surgical method for patients with HCC.

Previous studies have identified various factors that influence the prognosis of patients with HCC, such as age ([@b14-ol-0-0-11581]), tumor size ([@b15-ol-0-0-11581],[@b16-ol-0-0-11581]), marital status ([@b17-ol-0-0-11581]), α-fetoprotein level ([@b18-ol-0-0-11581]), lymph node involvement, metastasis and co-infection with hepatitis B and C viruses ([@b19-ol-0-0-11581]), Epstein-Barr virus-induced gene 3 ([@b20-ol-0-0-11581]), serum interleukin-34 (IL-34) ([@b21-ol-0-0-11581]), however their relative importance remains unclear.

Random forest (RF) is a widely used classification machine learning method that does not require a prior hypothesis ([@b22-ol-0-0-11581],[@b23-ol-0-0-11581]) and may provide another statistical option for researchers evaluating large datasets. RF has become a promising computational approach for determining patterns and associations based on high-dimensional datasets ([@b24-ol-0-0-11581]--[@b26-ol-0-0-11581]). The variable importance measure, a byproduct of the RF algorithm is calculated according to the predictive power of a variable and is often used to order the importance of variables, especially in genetics ([@b27-ol-0-0-11581]--[@b29-ol-0-0-11581]).

The Surveillance, Epidemiology and End Results (SEER) program collects data on cancer cases from various locations and sources throughout the USA, covering \~28% of the population ([@b30-ol-0-0-11581]). This dataset has been indicated to be valuable for predicting the prognosis of numerous types of malignant tumors, such as spinal ependymoma ([@b31-ol-0-0-11581]), breast carcinoma ([@b32-ol-0-0-11581]) and lung cancer ([@b33-ol-0-0-11581]).

In the present study, the RF model was used to identify the most important variables influencing the survival outcomes of patients with HCC. A longitudinal analysis was subsequently performed to determine the overall survival (OS) time and CSS outcomes of patients from SEER program with HCC ([www.seer.cancer.gov](www.seer.cancer.gov)) treated with different surgical methods, including no surgery, local tumor destruction, wedge or segmental resection, lobectomy and liver transplantation. The findings of the present study may provide clinicians and researchers with new evidence regarding HCC treatment selection.

Patients and methods
====================

### Population selection and data pre-processing

This cohort study was based on the newly released (1975--2016) Surveillance, Epidemiology and End Results (SEER) national database ([www.seer.cancer.gov](www.seer.cancer.gov)). Patients with an International Classification of Diseases Oncology, 3^rd^ Edition ([@b34-ol-0-0-11581]) code C220 and those with histology codes 8170--8175 were identified as cases with HCC. In total, 20,746 patients with HCC were identified who met the following inclusion criteria: ([@b1-ol-0-0-11581]) Diagnosed in 2004--2016, ([@b2-ol-0-0-11581]) diagnosed by histology methods and ([@b3-ol-0-0-11581]) aged ≥18 years. The exclusion criteria were no active follow-up data and missing values for surgery method, cancer-specific death, AFP, tumor size, historic stage and the T category according to the American Joint Committee on Cancer 6^th^ edition (AJCC6_T) (<https://seer.cancer.gov/seerstat/variables/seer/ajcc-stage/>). The detailed selection process is summarized in [Fig. 1](#f1-ol-0-0-11581){ref-type="fig"}.

The data for surgery methods was categorized into no surgery (no surgery of the primary site), local tumor destruction (including photodynamic therapy, electrocautery, cryosurgery, laser, percutaneous ethanol injection, heat RFA, ultrasound and use of acetic acid), wedge or segmental resection, lobectomy (including right lobectomy, left lobectomy, lobectomy and local tumor destruction and extended lobectomy), and liver transplantation groups. Surgery of other sites (distant lymph nodes or other tissue(s)/organ(s) beyond the primary site) was divided into a surgery group and a non-surgery group. The year of diagnosis was divided into three time periods: 2004--2008, 2009--2012 and 2013--2016. The data for scope of regional lymph node surgery were divided into a non-surgical group and a surgical group. Data for marital status were dichotomously divided into a married group and an unmarried group, which included those who were divorced, separated, single, unmarried, had a domestic partner or were widowed. In the present study, data regarding insurance as uninsured or insured were recoded. The insured group included those with Medicaid, Indian or a public health service or private insurance, and those \>65 years (as they were eligible for Medicare) ([@b35-ol-0-0-11581]).

### Presentation of data and statistics

Missing values consisted of 2.38% of the total data extracted; missing continuous variables were replaced with the mean and missing categorical variables were recorded as unknown. In [Table I](#tI-ol-0-0-11581){ref-type="table"}, continuous data are presented as mean ± SD and categorical data are presented as frequencies (%). One-way ANOVA, χ^2^ test and the Kruskal-Wallis H test were used to compare differences among the treatment groups for continuous, categorical and ordinal variables, respectively. All the post hoc tests were adjusted using Bonferroni\'s method. All the statistical analyses were performed using the R version 3.4.3 (<https://cran.r-project.org/>). Two-sided P-values \<0.05 were considered to indicate a statistically significant difference.

### Variable selection and importance ranking using RF analysis

For the generation of the RF model, the data included in the present study was first trained using general demographic information \[(age, insurance, education level ([@b36-ol-0-0-11581]), family income ([@b36-ol-0-0-11581]), race ([@b37-ol-0-0-11581]), marital status ([@b17-ol-0-0-11581]), sex ([@b38-ol-0-0-11581]), region)\] and factors that may be associated with survival outcomes according to previous studies and clinical practice as follows: Surgery method ([@b39-ol-0-0-11581]--[@b41-ol-0-0-11581]), tumor size ([@b15-ol-0-0-11581]), diagnosis year ([@b42-ol-0-0-11581]), historic stage, grade ([@b43-ol-0-0-11581]), AJCC_Tumor (T), AJCC_Node (N), AJCC_Metastasis (M) ([@b44-ol-0-0-11581]), scope of regional lymph node surgery, AFP ([@b18-ol-0-0-11581]), surgery of other sites, number of benign or borderline tumors and number of malignant tumors ([@b45-ol-0-0-11581]). Fibrosis score, radiation and chemotherapy were initially considered in the model, but were later excluded to preserve the power of the test as missing values accounted for over half of the population.

The RF model was employed to rank the importance of the predictors of HCC survival outcomes. This version of the RF model was performed in the R package 'randomForest' (v. 4.6--14) (<https://www.stat.berkeley.edu/~breiman/RandomForests/>). All data were randomly split into a training set and a validation set by a ratio of 6:4. The importance rankings of predictors of 2-year survival were obtained as a by-product of the RF model. The association between the top 10 most important predictors and 2-year survival outcome was analyzed using the logistic regression method.

### Comparison of surgical approaches using Cox regression analysis

Univariate Cox regression analysis was used to compare the overall survival (OS) time and CSS of patients with HCC treated with different surgical methods. To explore whether the association between surgical method and survival outcome is modified by other predictors, multivariate models were constructed using the 10 variables with the highest Gini index, which is a tool describing the relative contribution of each feature in predicting the outcome ([@b46-ol-0-0-11581]). In addition, analyses stratified by tumor size (patients were divided into two groups by median tumor size, cut-off value 54 mm), age (patients were divided into two groups by median age, cut-off value 62 years), histological stage and grade were conducted to minimize the effect of confounding factors.

Results
=======

### Predictive factors and comparison of surgical methods

A total of 20,746 patients diagnosed with HCC from 2004--2016 were included in the present study. The 10 most important factors influencing survival outcomes were surgery method, tumor size, age, AJCC_T, family income, education level, historic stage, grade, AJCC_M, and diagnosis year ([Fig. 2](#f2-ol-0-0-11581){ref-type="fig"}). Overall, local tumor destruction \[(hazard ratio (HR)=0.48; 95% confidence interval (CI), 0.45--0.51; P\<0.001)\], wedge or segmental resection (HR, 0.31; 95% CI, 0.29--0.33; P\<0.001), lobectomy (HR=0.29; 95% CI, 0.27--0.31; P\<0.001) and liver transplantation (HR=0.16; 95% CI; 0.14--0.17; P\<0.001) demonstrated improved OS outcomes compared with no surgery, except for undifferentiated tumors and those with distant metastasis, with the HRs demonstrating a decreasing trend ([Tables III](#tIII-ol-0-0-11581){ref-type="table"}, [SI](#SD1-ol-0-0-11581){ref-type="supplementary-material"} and [SIV](#SD1-ol-0-0-11581){ref-type="supplementary-material"}).

### Demographic and clinical characteristics of patients with HCC

Of the total patients with HCC, 2,568 had undergone liver transplantation, 1,574 lobectomy, 2,103 wedge or segmental resection and 2,466 local tumor destruction. A total of 12,035 patients had no surgery. All the 10 most important predictors were distributed unevenly among the 5 treatment groups (all P-values \<0.001). Post hoc analyses using Bonferroni\'s method demonstrated significant difference between the no surgery group and all 4 surgery groups (all P-values \<0.05). These detailed demographic and clinical characteristics of the patients are presented in [Table I](#tI-ol-0-0-11581){ref-type="table"}.

### Ranking of important predictors association with survival outcomes of patients with HCC based on the RF model

To compare the relative importance of predictive factors, an RF model using all predictors was first trained. This 21-predictor RF model achieved an accuracy of 78.05%, with ntree=1,400 (Number of trees to grow) and mtry=3 (Number of variables randomly sampled as candidates at each split). Based on the Gini index, the 10 most important predictors associated with the survival outcomes of patients with HCC were obtained. These were surgery method, tumor size, age, AJCC_T, family income, education level, historic stage, grade, AJCC_M and diagnosis year. The importance of the ranking results are presented in [Fig. 2](#f2-ol-0-0-11581){ref-type="fig"}. Next, 10 factors with the highest Gini were included in the subsequent analysis. The association between predictors and 2-year OS were further analyzed using the logistic regression method. The results indicated that more radical surgery methods, for example liver transplantation and lobectomy, higher family income and more recent diagnosis time, were protective predictive factors and that larger tumor size, older age, lower education level, metastasis, higher stage of AJCC_T and AJCC_M, less differentiated tissue were negative predictive factors ([Table II](#tII-ol-0-0-11581){ref-type="table"}).

### Cox regression analysis of survival outcomes for surgery methods among patients with HCC

In univariate Cox regression analysis, patients undergoing local tumor destruction (HR, 0.34; 95% CI, 0.32--0.36; P\<0.001), wedge or segmental resection (HR, 0.23; 95% CI, 0.22--0.25; P\<0.001), lobectomy (HR, 0.27; 95% CI, 0.25--0.29; P\<0.001) and liver transplantation (HR, 0.11; 95% CI, 0.10--0.12; P\<0.001) had improved overall survival time compared with patients not undergoing surgery ([Table III](#tIII-ol-0-0-11581){ref-type="table"}). Following adjustment for confounding factors in the multivariate analysis, this trend was weakened but remained significant. In multivariate analyses, patients undergoing local tumor destruction (HR, 0.48; 95% CI, 0.45--0.51; P\<0.001), wedge or segmental resection (HR, 0.31; 95% CI, 0.29--0.33; P\<0.001), lobectomy (HR, 0.29; 95% CI, 0.27--0.31; P\<0.001), and liver transplantation (HR, 0.16; 95% CI, 0.14--0.17; P\<0.001) had improved OS outcomes compared with patients not undergoing surgery ([Table III](#tIII-ol-0-0-11581){ref-type="table"}). Following adjustment, the HRs of local tumor destruction, wedge or segmental resection, lobectomy and liver transplantation demonstrated a decreasing trend, but there was no significant difference observed for wedge or segmental resection and lobectomy ([Table III](#tIII-ol-0-0-11581){ref-type="table"}). CSS analysis demonstrated a similar trend to OS for both univariate and multivariate analyses. Survival curves showed that patients undergoing liver transplantation had the longest survival time, and patients who did not undergo surgery had the shortest survival time compared with surgical methods (P\<0.001, [Fig. 3](#f3-ol-0-0-11581){ref-type="fig"}).

### Stratified analysis

To minimize the effect of confounding factors, stratified analyses were conducted based on tumor size (median tumor size, \<54 mm or ≥54 mm), age (median age, \<62 years or ≥62 years), historic stage (localized, regional or distant), and grade (grades I--IV). The stratified survival curves are presented in [Figs. S1](#SD1-ol-0-0-11581){ref-type="supplementary-material"}--[S4](#SD1-ol-0-0-11581){ref-type="supplementary-material"} and detailed information is provided in [Tables SI-SIV](#SD1-ol-0-0-11581){ref-type="supplementary-material"}. Altogether, the results demonstrated that the protective trend remained following stratification. However, there were two exceptions: In patients with distant metastasis and patients with undifferentiated tumors, no significant difference was observed for the four surgery types following stratification.

Discussion
==========

The present longitudinal study included 20,746 patients with HCC from the SEER database and a RF model was used to predict 2-year OS and CSS outcomes. Firstly, the relative importance of predictive factors was evaluated. Subsequently, the factor that was ranked most important, surgery method was further analyzed by Cox regression analysis. The the no surgery group, local tumor destruction group, wedge or segmental resection group, and lobectomy group demonstrated improved OS and CSS outcomes compared with liver transplantation group, with the HRs exhibiting a gradually decreasing trend overall. This result remained stable following stratification by tumor size, age, historic stage and grade, except for undifferentiated tumors and those with distant metastasis.

RF models are popular as they have high prediction accuracy and provide information on the relative importance of variables for classification ([@b47-ol-0-0-11581]). In recent years, the RF model has been commonly applied for investigating the quantitative importance of predictors for different cancers like pancreatic neuroendocrine tumors ([@b25-ol-0-0-11581]) and colorectal carcinoma ([@b48-ol-0-0-11581]); however, studies using this model on patients with HCC are very limited. Choi *et al* ([@b23-ol-0-0-11581]) constructed a prognostic model estimating the outcomes of 480 advanced-stage patients with HCC, all of whom were treated with sorafenib. Similarly, Kawaguchi *et al* ([@b49-ol-0-0-11581]) evaluated the prognosis of 247 patients with non-alcoholic fatty liver disease-HCC in Japan, indicating treatment and serum albumin level to be the two most important distinguishing factors. Our results suggested treatment was the most important prognostic factor, which was consistent with these studies. The present study had a large sample size and therefore provided a sTable result.

The 10 most important predictors found in the present study were surgery method (top of the list), tumor size, age, AJCC_T, family income, education level, historic stage, grade, AJCC_M and diagnosis year. Previous studies have suggested that RFA along with TACE prolongs the survival of patients with HCC ([@b9-ol-0-0-11581]) and that chemotherapy may achieve favorable results in patients with advanced HCC ([@b50-ol-0-0-11581]). However, in the present study, data on RFA therapy and chemotherapy was lacking for the majority of the study population; therefore, these methods were not investigated. No surgery and four surgery methods were discussed in the present study, including tumor destruction, wedge or segmental resection, lobectomy and transplantation. The findings of the present study demonstrated that liver transplantation was the first choice for all patients with HCC, except for those with undifferentiated tumors or distant metastasis. This result is consistent with previous studies, which have suggested that surgical resection offers a significant survival benefit over thermal ablation ([@b41-ol-0-0-11581]) and transarterial chemoembolization ([@b2-ol-0-0-11581]). Another study based on the SEER database (2013.5--2014.1) reported similar trends; local tumor destruction, partial surgery and total surgery compared with no surgery were all significant positive prognostic factors ([@b3-ol-0-0-11581]). The present study included more recently released data for participants, analyzed more treatment methods and applied more reliable variable selection criteria compared with the aforementioned study providing clinicians and researchers with more evidence. Other important outcome predictors, such as tumor size, age, AJCC_T, family income, education level, historic stage, grade, AJCC_M and diagnosis year, were consistent with previous studies. The present study is novel as it identified predictors according to their relative importance. Due to the limitations of the cohort studied, some important factors could not be included in the present study, such as genetic factors and cytokines, which are reported to be significantly associated with survival outcomes. For instance, EBI3 is suggested to be a cancer suppressor ([@b20-ol-0-0-11581]) and IL-34 may be associated with survival outcomes by regulating tumor growth and hepatic fibrosis in patients with HCC ([@b21-ol-0-0-11581]). Future prospective studies are required in order to investigate the relative importance of these factors.

The present study had several strengths. The RF model was used to rank the importance of variables associated with the survival outcomes of patients with HCC, providing new evidence to currently limited research. To date, studies utilizing the RF method to rank the importance of predictive clinical variables for patients with HCC are very limited ([@b23-ol-0-0-11581],[@b49-ol-0-0-11581]). The surgical methods included in the present study are broader and more detailed compared with those in previous studies. Besides, SEER collects data with a wide temporal and spatial range and the time of diagnosis was adjusted by multifactoral regression analysis considering that the treatment modality varies year by year. In total, 20,746 patients with HCC were included in the analysis, making the models very reliable. However, there are several limitations in the present study. First, as with any observational study, the effect of residual confounding or unmeasured factors cannot be completely ruled out inspite of the attempts to account for major potential confounders. Secondly, although, prognostic models for patients with HCC were generated with a large sample size, the present study lacked external validation. There is still a need to verify the results of the present study with external results for consistency.

The three most important predictors of survival outcomes of patients with HCC were surgery method, tumor size and education level. Liver transplantation had the best prognosis for patients with HCC, except for those with undifferentiated tumors or distant metastasis.
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![Patient selection criteria. A total of 20,746 patients with HCC were evaluated from the SEER national database ([www.seer.cancer.gov](www.seer.cancer.gov)) according to the exclusion and inclusion criteria outlined in the figure. HCC, hepatocellular carcinoma; SEER, Surveillance, Epidemiology and End Results; AFP, α fetoprotein; AJCC_T, the T category according to the American Joint Committee on Cancer 6th edition.](ol-20-01-0765-g00){#f1-ol-0-0-11581}

![Order of importance of predictive factors associated with the survival outcome of patients with HCC. The relative importance was ranked according to Gini index, which is a tool describing the relative contribution of each feature in predicting the outcome. Surgery, surgery of the primary site; tumor size, the largest dimension or diameter of the primary tumor; age, patient age at diagnosis; marital status, patients\' marital status at diagnosis; insurance, if patients had medical insurance at diagnosis; family income, median family income values by county; education, percentages of county populations (≥25 years) with less than a high school education between 2011--2015; historic stage, localized, regional and distant; grade, the degree of cell differentiation; diagnosis year, year of diagnosis; region, groups of countries at diagnosis; AFP, alpha fetoprotein; AJCC, the American Joint Committee on Cancer; T, tumor; N, node; M, metastasis; AJCC6_T, the T category according to the American Joint Committee on Cancer 6th edition; AJCC6_M, the M category according to the AJCC 6th edition; AJCC6_N, the N category according to the AJCC 6th edition; scope_reg_ln_sur, scope of regional lymph node surgery; in situ_malignant_tumor, total number of malignant tumors in patients; surg_oth_reg_dis, the surgical removal of distant lymph nodes or other tissues or organs beyond the primary site; benign_borderline_tumor, total number of benign or borderline tumors; HCC, hepatocellular carcinoma.](ol-20-01-0765-g01){#f2-ol-0-0-11581}

![Survival curves of 5 surgery methods (no surgery, local tumor destruction, wedge or segmental resection, lobectomy and liver transplantation) and number of patients at risk at different survival time (P-value represented the significance of the difference among survival curves of the 5 surgery methods).](ol-20-01-0765-g02){#f3-ol-0-0-11581}

###### 

Demographic and clinical characteristics of patients with hepatocellular carcinoma by categories of surgery methods.

  Characteristics                                                            No surgery      Local tumor destruction   Wedge or segmental resection   Lobectomy       Liver transplantation   Statistics       P-value
  -------------------------------------------------------------------------- --------------- ------------------------- ------------------------------ --------------- ----------------------- ---------------- ---------
  Diagnosis year, n (%)                                                                                                                                                                       Kruskal-Wallis   \<0.001
                                                                                                                                                                                              χ2=188.0         
    2004-2008                                                                3,531 (29.34)   923 (37.43)                 575 (27.34)                    519 (32.97)     1008 (39.25)                           
    2009-2012                                                                3,929 (32.65)   722 (29.28)                 663 (31.53)                    517 (32.85)     855 (33.29)                            
    2013-2015                                                                4,575 (38.01)   821 (33.29)                 865 (41.13)                    538 (34.18)     705 (27.45)                            
  Age, mean ± SD^[a](#tfn1-ol-0-0-11581){ref-type="table-fn"}^               64.17±11.32     63.19±10.00               62.06±11.08                    61.52±12.64     57.64±7.63              F=201.2          \<0.001
  Education level^[b](#tfn2-ol-0-0-11581){ref-type="table-fn"}^, mean ± SD   14.89±5.94      13.81±5.50                14.34±5.54                     14.21±5.73      14.08±5.83              F=26.3           \<0.001
  Family income^[c](#tfn3-ol-0-0-11581){ref-type="table-fn"}^, mean ± SD     75.76±19.27     80.89±19.43               80.80±20.60                    82.27±20.85     77.49±20.20             F=79.8           \<0.001
  Tumor size, mm, mean ± SD                                                  72.09±46.08     41.23±27.78               53.85±41.50                    82.78±54.40     33.36±24.49             F=724.4          \<0.001
  Histological stage,                                                                                                                                                                         Kruskal-Wallis   \<0.001
  n (%)                                                                                                                                                                                       χ2=3,269.7       
    Localized                                                                4,899 (40.71)   1,917 (77.74)             1,720 (81.79)                  1,142 (72.55)   2,022 (78.74)                            
    Regional                                                                 4,250 (35.31)     482 (19.55)               333 (15.83)                    356 (22.62)     528 (20.56)                            
    Distant                                                                  2,886 (23.98)     67 (2.72)                 50 (2.38)                      76 (4.83)       18 (0.70)                              
  AJCC_T n (%)^[e](#tfn5-ol-0-0-11581){ref-type="table-fn"}^                                                                                                                                  χ2=2,639.3       \<0.001
    T1                                                                       3,764 (31.28)   1,372 (55.64)             1,130 (53.73)                    664 (42.19)   1,216 (47.35)                            
    T2                                                                       2,182 (18.13)     632 (25.63)               494 (23.49)                    350 (22.24)   1,077 (41.94)                            
    T3                                                                       4,097 (34.04)   227 (9.21)                  202 (9.61)                     339 (21.54)     129 (5.02)                             
    T4                                                                         603 (5.01)      24 (0.97)                 59 (2.81)                      87 (5.23)       17 (0.66)                              
    TX                                                                       1,389 (11.54)   211 (8.56)                  218 (10.37)                    134 (8.51)      129 (5.02)                             
  AJCC_N n (%)^[f](#tfn6-ol-0-0-11581){ref-type="table-fn"}^                                                                                                                                    χ2=1,082.1     \<0.001
    N0                                                                       8,566 (71.18)   2,134 (86.54)             1831 (87.07)                   1,373 (87.23)   2,384 (92.83)                            
    N1                                                                       1,225 (10.18)     48 (1.95)                 22 (1.05)                      45 (2.86)       20 (0.78)                              
    NX                                                                       2,244 (18.65)     284 (11.52)               250 (11.89)                    156 (9.91)      164 (6.39)                             
  AJCC_M n (%)^[g](#tfn7-ol-0-0-11581){ref-type="table-fn"}^                                                                                                                                  χ2=1,897.8       \<0.001
    M0                                                                       7,946 (66.02)   2,179 (88.36)             1,834 (87.21)                  1,379 (87.61)   2,414 (94.00)                            
    M1                                                                       2,425 (20.15)     57 (2.31)                 39 (1.85)                      50 (3.18)       16 (0.62)                              
    MX                                                                       1,664 (13.83)   230 (9.33)                  230 (10.94)                    145 (9.21)      138 (5.37)                             
  Grade, n (%)^[d](#tfn4-ol-0-0-11581){ref-type="table-fn"}^                                                                                                                                    χ2=2,058.9     \<0.001
    I                                                                        2,299 (19.10)     624 (25.30)               396 (18.83)                    246 (15.63)     557 (21.69)                            
    II                                                                       2,785 (23.14)     736 (29.85)             1,019 (48.45)                    773 (49.11)   1,008 (39.25)                            
    II                                                                       1,598 (13.28)   199 (8.07)                  446 (21.21)                    370 (23.51)     220 (8.57)                             
    IV                                                                         136 (1.13)      9 (0.36)                  31 (1.47)                      46 (2.92)       14 (0.55)                              
    Unknown                                                                  5,217 (43.35)     898 (36.42)               211 (10.03)                    139 (8.83)      769 (29.95)                            

Patients age at diagnosis

Percentages of county populations (≥25%) with less than a high school education between 2013--2017

Median family income values by county, income is displayed as dollars in thousands

Grade I, well differentiated; Grade II, moderately differentiated; Grade III, poorly differentiated; Grade IV, undifferentiated.

AJCC_T, the T category according to the American Joint Committee on Cancer 6th edition

AJCC_N, the N category according to the American Joint Committee on Cancer 6th edition

AJCC_M, the M category according to the American Joint Committee on Cancer 6th edition.

###### 

Logistic regression analysis of 2-year survival and predictors in patients with hepatocellular carcinoma.

                                                             Univariate analysis   Multivariate analysis^[a](#tfn8-ol-0-0-11581){ref-type="table-fn"}^                                      
  ---------------------------------------------------------- --------------------- --------------------------------------------------------------------- --------- ----------- ------------ ---------
  Surgery method                                                                                                                                                                            
    No surgery                                               Reference                                                                                             Reference                \<0.001
    Local tumor destruction                                  0.18                  0.16--0.20                                                            \<0.001   0.29        0.26--0.32   \<0.001
    Wedge or segmental resection                             0.10                  0.09--0.12                                                            \<0.001   0.15        0.13--0.16   \<0.001
    Lobectomy                                                0.15                  0.13--0.16                                                            \<0.001   0.13        0.11--0.15   \<0.001
    Liver transplantation                                    0.05                  0.05--0.06                                                            \<0.001   0.08        0.07--0.10   \<0.001
  Tumor size, mm                                             1.02                  1.02--1.02                                                            \<0.001   1.01        1.01--1.01   \<0.001
  Age, years^[a](#tfn8-ol-0-0-11581){ref-type="table-fn"}^   1.02                  1.02--1.02                                                            \<0.001   1.01        1.01--1.02   \<0.001
  Education level                                            1.01                  1.01--1.02                                                            \<0.001   0.98        0.98--0.99   \<0.001
  Family income                                              0.99                  0.99--0.99                                                            \<0.001   0.99        0.99--0.99   \<0.001
  Historic stage                                                                                                                                                                            
    Localized                                                Reference                                                                                             Reference                
    Regional                                                 5.78                  5.34--6.28                                                            \<0.001   2.32        1.97--2.73   \<0.001
    Distant                                                  1.04                  0.98--1.11                                                            0.202     1.09        0.98--1.22   0.105
  AJCC_T                                                                                                                                                                                    
    T1                                                       Reference                                                                                             Reference                
    T2                                                       1.17                  1.09--1.26                                                            \<0.001   1.21        1.10--1.33   \<0.001
    T3                                                       5.50                  5.06--5.97                                                            \<0.001   1.77        1.58--1.98   \<0.001
    T4                                                       7.00                  5.78--8.54                                                            \<0.001   1.66        1.31--2.12   \<0.001
  Diagnosis year                                                                                                                                                                            
    2004-2008                                                Reference                                                                                             Reference                
    2009-2012                                                0.88                  0.82--0.94                                                            \<0.001   0.72        0.66--0.79   \<0.001
    2013-2015                                                0.57                  0.54--0.61                                                            \<0.001   0.48        0.44--0.53   \<0.001
  Grade                                                                                                                                                                                     
    I                                                        Reference                                                                                             Reference                
    II                                                       0.97                  0.90--1.06                                                            \<0.001   1.30        1.18--1.43   \<0.001
    III                                                      2.22                  2.01--2.45                                                            \<0.001   2.44        2.15--2.76   \<0.001
    IV                                                       3.34                  2.50--4.51                                                            \<0.001   3.68        2.59--5.29   \<0.001
  AJCC_M                                                     2.04                  1.89--2.21                                                            \<0.001                            
    M0                                                       Reference                                                                                             Reference                
    M1                                                       11.69                 10.14--13.55                                                          \<0.001   1.74        1.33--2.27   \<0.001

Age was analyzed as a continuous variable. OR, odd ratio; CI, confidence interval; T, Tumor; N, Node; M, Metastasis; AJCC, the American Joint Committee on Cancer.

###### 

Cox regression and competing risk analysis for association of survival outcomes with surgery types in patients with HCC.

  A, Univariate analysis                                                                                                                                                 
  ---------------------------------------------------------------------------- ---------------------- ------------------------------ ------------- -------- ------------ -------------
  No surgery                                                                   Reference                                                                                 
  Local tumor destruction                                                      0.34                   0.32--0.36                     \<0.001       0.31     0.29--0.33   \<0.001
  Wedge or segmental resection                                                 0.23                   0.22--0.25                     \<0.001       0.22     0.20--0.24   \<0.001
  Lobectomy                                                                    0.27                   0.25--0.29                     \<0.001       0.26     0.24--0.28   \<0.001
  Liver transplantation                                                        0.11                   0.10--0.12                     \<0.001       0.07     0.07--0.08   \<0.001
                                                                                                                                                                         
  **B, Multivariate analysis^[a](#tfn9-ol-0-0-11581){ref-type="table-fn"}^**                                                                                             
                                                                                                                                                                         
                                                                               **Overall survival**   **Cancer-specific survival**                                       
                                                                                                                                                                         
  **Variable**                                                                 **HR**                 **95% CI**                     **P-value**   **HR**   **95% CI**   **P-value**
                                                                                                                                                                         
  No surgery                                                                   Reference                                                                                 
  Local tumor destruction                                                      0.48                   0.45--0.51                     \<0.001       0.46     0.43--0.49   \<0.001
  Wedge or segmental resection                                                 0.31                   0.29--0.33                     \<0.001       0.30     0.28--0.32   \<0.001
  Lobectomy                                                                    0.29                   0.27--0.31                     \<0.001       0.28     0.26--0.31   \<0.001
  Liver transplantation                                                        0.16                   0.14--0.17                     \<0.001       0.11     0.10--0.12   \<0.001

The 10 most important predictors were included in the multivariate models. HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; T, Tumor; N, Node; M, Metastasis; AJCC, the American Joint Committee on Cancer.

[^1]: Contributed equally
